User profiles for J. Van Meerbeeck

Jan P van Meerbeeck

Universiteit Antwerpen - Universitair Ziekenhuis Antwerpen- Universiteit Gent
Verified email at uza.be
Cited by 40170

Small-cell lung cancer

JP Van Meerbeeck, DA Fennell, DKM De Ruysscher - The Lancet, 2011 - thelancet.com
The incidence and mortality of small-cell lung cancer worldwide make this disease a notable
health-care issue. Diagnosis relies on histology, with the use of immunohistochemical …

[HTML][HTML] The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the …

…, M Marino, EM Marom, J van Meerbeeck… - Journal of Thoracic …, 2016 - Elsevier
This article proposes codes for the primary tumor categories of adenocarcinoma in situ (AIS)
and minimally invasive adenocarcinoma (MIA) and a uniform way to measure tumor size in …

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.

…, T Sahmoud, P Therasse, J van Meerbeeck… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE Identification of prognostic factors in patients with malignant pleural mesothelioma
based on prospectively collected international data. PATIENTS AND METHODS From …

[HTML][HTML] The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung …

…, M Marino, EM Marom, J van Meerbeeck… - Journal of Thoracic …, 2016 - Elsevier
The IASLC Staging and Prognostic Factors Committee has collected a new database of
94,708 cases donated from 35 sources in 16 countries around the globe. This has now been …

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

…, V Pancaldi, AM Dingemans, J Van Meerbeeck… - The Lancet …, 2020 - thelancet.com
Background Early reports on patients with cancer and COVID-19 have suggested a high
mortality rate compared with the general population. Patients with thoracic malignancies are …

[HTML][HTML] Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

…, H Senellart, J Van Meerbeeck, J Raskin… - … England Journal of …, 2020 - Mass Medical Soc
Background A splice-site mutation that results in a loss of transcription of exon 14 in the
oncogenic driver MET occurs in 3 to 4% of patients with non–small-cell lung cancer (NSCLC). …

Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma

…, P Van Houtte, J Van Meerbeeck… - European …, 2010 - Eur Respiratory Soc
… In the study by van Meerbeeck et al. 42, the median number of cisplatin-raltitrexed cycles
was five (from one to 10 cycles). We do not have data on the potential advantage of delivering …

[PDF][PDF] Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European …

JP van Meerbeeck, R Gaafar, C Manegold… - Journal of Clinical …, 2005 - researchgate.net
Purpose We conducted a phase III trial to determine whether first-line treatment with
raltitrexed, a thymidine synthase inhibitor, and cisplatin results in superior outcome …

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non–small-cell lung cancer

JP Van Meerbeeck, GWPM Kramer… - Journal of the …, 2007 - academic.oup.com
van Meerbeeck , … van Meerbeeckvan Meerbeeck, Gijs WPM Kramer, Paul EY Van Schil,
Catherine Legrand, Egbert F. Smit, Franz Schramel, Vivianne C. Tjan-Heijnen, Bonne Biesma, …

[HTML][HTML] Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

L Crino, W Weder, J Van Meerbeeck… - Annals of …, 2010 - annalsofoncology.org
Lung cancer represents the leading cause of cancer mortality worldwide, accounting for 1.2
million deaths each year. Improving survival in lung cancer is a major challenge for modern …